Since all tumor samples in our studies were collected before chemotherapy we presume that the observed hypermethylation of SLFN11 in the analyzed tumors confers a growth advantage in these cells and it is also a biomarker of primary resistance to the mentioned drugs. This evidence concerns the gene SLFN11 and neoplasm.